

## AroCell - Good cost control, somewhat lower sales

Redeye returns with a more detailed take on the Q2 report and notes lower costs than expected and anticipate a continuous upswing of TUBEX sales while lowering FY 2022E sales somewhat. We reiterate our fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[AroCell - Good cost control, somewhat lower sales](#)